JPWO2020102375A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020102375A5 JPWO2020102375A5 JP2021526256A JP2021526256A JPWO2020102375A5 JP WO2020102375 A5 JPWO2020102375 A5 JP WO2020102375A5 JP 2021526256 A JP2021526256 A JP 2021526256A JP 2021526256 A JP2021526256 A JP 2021526256A JP WO2020102375 A5 JPWO2020102375 A5 JP WO2020102375A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- inhibitor
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024102591A JP2024123216A (ja) | 2018-11-14 | 2024-06-26 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767218P | 2018-11-14 | 2018-11-14 | |
| US62/767,218 | 2018-11-14 | ||
| PCT/US2019/061212 WO2020102375A1 (en) | 2018-11-14 | 2019-11-13 | Intralesional administration of pd-1 inhibitors for treating skin cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102591A Division JP2024123216A (ja) | 2018-11-14 | 2024-06-26 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513029A JP2022513029A (ja) | 2022-02-07 |
| JPWO2020102375A5 true JPWO2020102375A5 (https=) | 2022-11-07 |
| JP2022513029A5 JP2022513029A5 (https=) | 2022-11-07 |
| JP7513604B2 JP7513604B2 (ja) | 2024-07-09 |
Family
ID=68841191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526256A Active JP7513604B2 (ja) | 2018-11-14 | 2019-11-13 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
| JP2024102591A Pending JP2024123216A (ja) | 2018-11-14 | 2024-06-26 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102591A Pending JP2024123216A (ja) | 2018-11-14 | 2024-06-26 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12473364B2 (https=) |
| EP (2) | EP3880186B1 (https=) |
| JP (2) | JP7513604B2 (https=) |
| CN (1) | CN113038939A (https=) |
| DK (1) | DK3880186T3 (https=) |
| ES (1) | ES2980363T3 (https=) |
| FI (1) | FI3880186T3 (https=) |
| HR (1) | HRP20240825T1 (https=) |
| HU (1) | HUE067601T2 (https=) |
| LT (1) | LT3880186T (https=) |
| PL (1) | PL3880186T3 (https=) |
| PT (1) | PT3880186T (https=) |
| RS (1) | RS65627B1 (https=) |
| SI (1) | SI3880186T1 (https=) |
| SM (1) | SMT202400252T1 (https=) |
| WO (1) | WO2020102375A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| EP4313123A1 (en) * | 2021-03-23 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| EP2195342A1 (en) | 2007-09-07 | 2010-06-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| KR102228296B1 (ko) | 2012-03-16 | 2021-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물 |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| JP6295998B2 (ja) | 2015-05-12 | 2018-03-20 | 株式会社デンソー | 内燃機関の再始動制御装置 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| EP3402517B1 (en) | 2016-01-15 | 2025-08-20 | RFEMB Holdings, LLC | Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf |
| CN109310677A (zh) | 2016-04-07 | 2019-02-05 | 凯莫森特里克斯股份有限公司 | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| WO2018106862A1 (en) * | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| KR20240011262A (ko) | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
| US10166290B2 (en) | 2017-02-24 | 2019-01-01 | Max H. Cohen | Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2019
- 2019-11-13 HU HUE19817846A patent/HUE067601T2/hu unknown
- 2019-11-13 PL PL19817846.9T patent/PL3880186T3/pl unknown
- 2019-11-13 US US17/292,179 patent/US12473364B2/en active Active
- 2019-11-13 HR HRP20240825TT patent/HRP20240825T1/hr unknown
- 2019-11-13 PT PT198178469T patent/PT3880186T/pt unknown
- 2019-11-13 SM SM20240252T patent/SMT202400252T1/it unknown
- 2019-11-13 EP EP19817846.9A patent/EP3880186B1/en active Active
- 2019-11-13 RS RS20240682A patent/RS65627B1/sr unknown
- 2019-11-13 FI FIEP19817846.9T patent/FI3880186T3/fi active
- 2019-11-13 SI SI201930759T patent/SI3880186T1/sl unknown
- 2019-11-13 JP JP2021526256A patent/JP7513604B2/ja active Active
- 2019-11-13 CN CN201980074748.7A patent/CN113038939A/zh active Pending
- 2019-11-13 DK DK19817846.9T patent/DK3880186T3/da active
- 2019-11-13 WO PCT/US2019/061212 patent/WO2020102375A1/en not_active Ceased
- 2019-11-13 ES ES19817846T patent/ES2980363T3/es active Active
- 2019-11-13 EP EP24158793.0A patent/EP4382168A3/en active Pending
- 2019-11-13 LT LTEPPCT/US2019/061212T patent/LT3880186T/lt unknown
-
2024
- 2024-06-26 JP JP2024102591A patent/JP2024123216A/ja active Pending
-
2025
- 2025-10-24 US US19/368,062 patent/US20260042841A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515008A5 (https=) | ||
| IL308805A (en) | Anti-pd-1 antibodies for treatment of lung cancer | |
| JP2020508317A5 (https=) | ||
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2022033868A5 (https=) | ||
| JP2022126791A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| CN109999195A (zh) | 类风湿关节炎的治疗 | |
| HK1213782A1 (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| IL278400B2 (en) | Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer | |
| HRP20240825T1 (hr) | Intralezijsko davanje pd-1 inhibitora za liječenje raka kože | |
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JPWO2021113701A5 (https=) | ||
| JPWO2021224499A5 (https=) | ||
| JPWO2020102375A5 (https=) | ||
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 | |
| RU2021128133A (ru) | Введение ингибиторов pd-1 для лечения рака кожи | |
| JPWO2021016233A5 (https=) | ||
| RU2024129390A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕЙ ЭПИТЕЛИОИДНОЙ САРКОМЫ С ПОМОЩЬЮ БИСПЕЦИФИЧНЫХАНТИТЕЛ ПРОТИВ MUC16 x CD3 САМИХ ПО СЕБЕ ИЛИ В КОМБИНАЦИИ С АНТИТЕЛАМИ ПРОТИВ PD-1 | |
| RU2026104179A (ru) | Способы лечения множественной миеломы | |
| JP2021524446A5 (https=) | ||
| JPWO2023177772A5 (https=) | ||
| RU2025126669A (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности лечения меланомы | |
| RU2025138318A (ru) | Способы лечения множественной миеломы |